Overview

Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A

Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the relative bioavailability of ReFacto AF as compared to ReFacto, when each is administered as 2-minute bolus infusions.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Factor VIII